PRFX קפיטליזציה חשבונאית PainReform
PainReform Ltd. (PRFX) specializes in developing innovative solutions for long-term postoperative pain management, utilizing technology that optimizes clinic service costs by accelerating patient recovery. Business growth is driven by the completion of final PRF-110 trials and pending FDA approval. The current metric stands at 0.00. The quotes provided below on GURU.Markets complement data regarding a stable expert staff and low employee turnover.
%20%D7%A9%D7%95%D7%95%D7%99%20%D7%94%D7%97%D7%91%D7%A8%D7%94%20%D7%91%D7%A1%D7%A4%D7%A8%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_PRFX_-_PainReform-Ltd._-_Company-Book-Value "PainReform Ltd (PRFX): שווי נכסים נקי מ-04.07.2022 עד 27.10.2026 | 👁️GURU.Markets👁️")
פילוחי מדדים ואנליטיקה של חברת PainReform (PRFX)
Book value, represented by the current carrying amount of equity, measures the residual value of net assets after all liabilities are settled, establishing the fundamental safety threshold for investments. For PainReform Ltd. (PRFX), this indicator serves as a defensive buffer during the completion of PRF-110 clinical trials, allowing for an assessment of the business's actual material stability prior to receiving regulatory approvals and a potential revision of market value.